GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alkermes PLC (NAS:ALKS) » Definitions » Pretax Margin %

Alkermes (Alkermes) Pretax Margin % : 48.28% (As of Dec. 2023)


View and export this data going back to 1991. Start your Free Trial

What is Alkermes Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Alkermes's Pre-Tax Income for the three months ended in Dec. 2023 was $182 Mil. Alkermes's Revenue for the three months ended in Dec. 2023 was $377 Mil. Therefore, Alkermes's pretax margin for the quarter that ended in Dec. 2023 was 48.28%.

The historical rank and industry rank for Alkermes's Pretax Margin % or its related term are showing as below:

ALKS' s Pretax Margin % Range Over the Past 10 Years
Min: -35.65   Med: -10.45   Max: 25.34
Current: 25.34


ALKS's Pretax Margin % is ranked better than
90.22% of 1022 companies
in the Drug Manufacturers industry
Industry Median: 4.555 vs ALKS: 25.34

Alkermes Pretax Margin % Historical Data

The historical data trend for Alkermes's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alkermes Pretax Margin % Chart

Alkermes Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.83 -9.29 7.47 -2.80 25.34

Alkermes Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.58 -16.64 38.83 12.43 48.28

Competitive Comparison of Alkermes's Pretax Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Alkermes's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alkermes's Pretax Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alkermes's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Alkermes's Pretax Margin % falls into.



Alkermes Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Alkermes's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=421.519/1663.405
=25.34 %

Alkermes's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=182.26/377.475
=48.28 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alkermes  (NAS:ALKS) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Alkermes Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Alkermes's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Alkermes (Alkermes) Business Description

Traded in Other Exchanges
Address
1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.
Executives
Cato T Laurencin director C/O UNIVERSITY OF CONNECTICUT, 263 FARMINGTON AVENUE, FARMINGTON CT 06030-3800
Christian Todd Nichols officer: SVP, Chief Commercial Officer 852 WINTER STREET, WALTHAM MA 02451
Nancy Wysenski director 2200 SUNBURST STREET, CHATSWORTH CA 90401
Daglio David Angelo Jr. director ALKERMES, 852 WINTER STREET, WALTHAM MA 02451
Christopher I Wright director C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Michael J Landine officer: SVP, Corp Dev., Alkermes, Inc. 88 SIDNEY ST, CAMBRIDGE MA 021394136
Richard F Pops director, officer: Director and CEO, Alkermes plc 10555 SCIENCE CENTER DR, SAN DIEGO CA 92121
Shane Cooke officer: President, Alkermes plc TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000
Blair Curtis Jackson officer: EVP, Chief Operating Officer 852 WINTER STREET, WALTHAM MA 02451
Snyderman Nancy Lynn Md director 37 PHEASANT HILL ROAD, PRINCETON NJ 08540
Craig C. Hopkinson officer: SVP, Med Dev/Med Affairs, CMO 852 WINTER STREET, WALTHAM MA 02451
Emily Peterson Alva director C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Iain Michael Brown officer: VP, Finance & CAO 14 ROYALSTON AVENUE, WINCHESTER MA 01890
Brian P Mckeon director IDEXX LABORATORIES, ONE IDEXX DRIVE, WESTBROOK ME 04092
David Joseph Gaffin officer: SVP, CLO, Alkermes, Inc. 852 WINTER STREET, WALTHAM MA 02451